FDA Panel Endorses GRAIL's Galleri Test; GRAL Stock Reflects High Price-to-Sales Amid Unprofitability
· gurufocus.com
On September 23, 2026, a U.S. FDA advisory panel voted 6-4 in favor of GRAIL Inc's (NASDAQ: GRAL) Galleri multi-cancer early detection blood test, deeming it re
On September 23, 2026, a U.S. FDA advisory panel voted 6-4 in favor of GRAIL Inc’s (NASDAQ: GRAL) Galleri multi-cancer early detection blood test, deeming it ...